Shares of NewLink Genetics Corp. (NASDAQ:NLNK) have been given a consensus recommendation of “Hold” by the eight analysts that are presently covering the company. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $25.40.
Separately, Zacks Investment Research cut shares of NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th.
A number of large investors have recently made changes to their positions in the stock. American International Group Inc. increased its stake in shares of NewLink Genetics Corp. by 1.4% in the second quarter. American International Group Inc. now owns 12,455 shares of the company’s stock valued at $140,000 after buying an additional 174 shares in the last quarter. ProShare Advisors LLC increased its stake in NewLink Genetics Corp. by 1.0% in the second quarter. ProShare Advisors LLC now owns 24,157 shares of the company’s stock worth $272,000 after buying an additional 250 shares in the last quarter. Zacks Investment Management increased its stake in NewLink Genetics Corp. by 2.1% in the second quarter. Zacks Investment Management now owns 24,166 shares of the company’s stock worth $272,000 after buying an additional 506 shares in the last quarter. Nationwide Fund Advisors increased its stake in NewLink Genetics Corp. by 5.8% in the second quarter. Nationwide Fund Advisors now owns 14,160 shares of the company’s stock worth $159,000 after buying an additional 770 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in NewLink Genetics Corp. by 5.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 21,334 shares of the company’s stock worth $240,000 after buying an additional 1,164 shares in the last quarter. 50.10% of the stock is owned by institutional investors and hedge funds.
Shares of NewLink Genetics Corp. (NASDAQ:NLNK) traded down 7.12% during midday trading on Thursday, reaching $14.61. 362,405 shares of the company’s stock traded hands. The stock’s market cap is $423.24 million. NewLink Genetics Corp. has a 52-week low of $9.23 and a 52-week high of $46.34. The stock has a 50 day moving average of $11.44 and a 200-day moving average of $12.76.
NewLink Genetics Corp. (NASDAQ:NLNK) last released its earnings results on Friday, July 29th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.35. NewLink Genetics Corp. had a negative net margin of 316.38% and a negative return on equity of 51.33%. On average, equities research analysts expect that NewLink Genetics Corp. will post ($3.06) EPS for the current year.
NewLink Genetics Corp. Company Profile
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.
Receive News & Ratings for NewLink Genetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.